Biogen Idec reports favourable data from Phase IIa Parkinson’s Disease studies licensed from VernalisVernalis plc today announced that Biogen Idec presented headline data at its 25 March 2009 R&D Day from two Phase IIa studies of BIIB014 (also known as V2006), an oral compound for the treatment of Parkinson’s disease.
In a press release, Biogen Idec announced that interim results from these Phase IIa studies of BIIB014 were favorable and support continued development of BIIB014 in patients with Parkinson’s disease. Biogen Idec also announced that it is currently in discussion with regulators surrounding the design of a registration program of BIIB014 in this patient population. In a presentation at its R&D Day, Biogen Idec reported that BIIB014 was well tolerated and showed dose dependent clinically relevant effects in patients with both early and late stage Parkinson’s disease.
In June 2004, Vernalis entered into an agreement with Biogen Idec to develop and commercialise BIIB014. Biogen Idec is conducting and funding future development and will pay milestones and royalties on the successful development and commercialisation of the product.
BIIB014 is a once-daily oral adenosine A2A receptor antagonist that may offer a non-dopaminergic therapy for patients with Parkinson’s disease.
Ian Garland, CEO of Vernalis commented:
“We are delighted that Biogen Idec has announced favourable Phase IIa data for BIIB014 and that these data support continued development of this novel compound as a treatment for patients with Parkinson’s disease. I am pleased that this compound, discovered by Vernalis, has the potential to be a novel, non-dopaminergic treatment option for the very many people with Parkinson’s disease. “
No comments:
Post a Comment